Want to see DMRA full AI Analyst Report?
Damora Therapeutics (DMRA) Stock Price & Analysis
DMRA Stock Chart & Stats
- Day’s Range
- $20.75 - $24.80
- 52-Week Range
- $4.95 - $38.33
- Previous Close
- $22.94
- Volume
- N/A
- Average Volume (3M)
- 515.13K
- Market Cap
- $1.42B
- Enterprise Value
- $918.32M
- Total Cash (Recent Filing)
- $528.48M
- Total Debt (Recent Filing)
- $1.10M
- Price to Earnings (P/E)
- ―
- Beta
- 0.03
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- -0.55
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage reduces solvency pressure and preserves financial flexibility while Damora funds development. A lightly indebted balance sheet can support future investment or partnership decisions without the fixed repayment burden that would further strain an early-stage biotech.
Improved Cash Burn
The materially smaller cash outflow indicates improved cash discipline or reduced operating demands compared with the prior year. Although burn remains negative, sustaining this improvement would extend financial runway and give management more time to advance clinical programs.
Clinical And Regulatory Progress
FDA clearance and multi-site enrollment represent concrete progress from research toward clinical development for DMR-001. Additional regional submissions could broaden trial execution and increase the pipeline's strategic value if the program continues to generate supportive data.
Bears Say
No Revenue
The absence of revenue means Damora currently lacks an operating commercial base to fund research, development, or corporate costs. Financial performance therefore depends on advancing candidates toward future commercialization rather than on an established recurring business.
Widening Net Loss
The sharp increase in annual losses shows that profitability remains highly negative and volatile as the company invests in development. Continued large losses can reduce equity value and increase the amount of capital required before Damora reaches sustainable operating leverage.
Persistent Negative Cash Flow
Persistent cash burn limits internal funding capacity and leaves Damora reliant on external capital while its candidates remain in development. That dependence can constrain strategic flexibility and create recurring financing needs before any product revenue is established.
Damora Therapeutics News
Analyst Reiterates Buy on Damora, Citing mutCALR Leadership and Strong Pipeline with Unchanged $45 Price Target
Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Damora Therapeutics. The associated price target remains the same with $45.00. Sam Slutsky has given his Buy rating
Analyst Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target on Differentiated Clinical Strategy
H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on DMRA stock, giving a Buy rating today. Mitchell Kapoor has given his Buy rating due to a combination of
Analyst Initiates Buy on Damora Therapeutics Citing Strong mCALR Pipeline, Accelerated CLARITY-101 Readouts, and Funding Runway Into 2029
TD Cowen analyst Marc Frahm has maintained their bullish stance on DMRA stock, giving a Buy rating on August 6. Marc Frahm has given his Buy rating due to a
Sam Slutsky Reiterates Buy Rating on Damora Therapeutics, Maintains $45 Price Target on Promising DMR-001 Profile
Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Damora Therapeutics. The associated price target remains the same with $45.00. Sam Slutsky has given his Buy rating
DMRA FAQ
What was Damora Therapeutics’s price range in the past 12 months?
What is Damora Therapeutics’s market cap?
When is Damora Therapeutics’s upcoming earnings report date?
How were Damora Therapeutics’s earnings last quarter?
Is Damora Therapeutics overvalued?
Does Damora Therapeutics pay dividends?
What is Damora Therapeutics’s EPS estimate?
How many shares outstanding does Damora Therapeutics have?
What happened to Damora Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Damora Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Damora Therapeutics Stock Smart Score
Company Description
Damora Therapeutics
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jennifer A. Jarrett
- Employees
- 7
- Website
- www.damoratx.com
- Address
- Building 23, Waltham, MA, 02453, US
Damora Therapeutics (DMRA) Earnings & Revenues
DMRA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 9 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 4 | 0 | 8 |
